Single-dose DT120 ODT delivers rapid, sustained anxiety relief in phase 3 GAD trial, supporting FDA breakthrough path and NDA plans.
|Articles|April 24, 2020
COVID-19: What Lies Ahead in Mental Health?
Author(s)Michelle Riba, MD, MS, DFAPA, FAPM
Michelle Riba, MD, shares her thoughts on the days ahead.
Advertisement
Patients with depression, anxiety, and other mental health problems are going to need us more ever in the days ahead. Dr Riba is Professor and Associate Chair, University of Michigan Department of Psychiatry; Associate Director, University of Michigan Comprehensive Depression Center; and Deputy Editor in Chief Emeritus, Psychiatric Times. University of Michigan Department of Psychiatry has an excellent resources page on its website:
Advertisement
Related to this article
Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.
Discuss depression care challenges, comorbidities, and new treatments—submit cases, research, or CME ideas for Psychiatric Times’ September 2026 series.
Yale trio-genomics study links hair-pulling and skin-picking to inherited OCD risk scores and rare DNA variants, hinting at shared brain pathways.
BioVie completes treatment visits in a phase 2 long COVID trial of bezisterim targeting brain fog and fatigue, with topline results expected September 2026.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Vol 43, Issue 9 - Interactive
2
FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval
3
Debunking the Top 10 Misleading Claims About Antidepressants
4
What Low Doses of VRAYLAR® (Cariprazine) May Mean for Clinical Practice
5